We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RBCC Forms Joint Venture with Cutting-Edge Drug Delivery Company TheraKine
News

RBCC Forms Joint Venture with Cutting-Edge Drug Delivery Company TheraKine

RBCC Forms Joint Venture with Cutting-Edge Drug Delivery Company TheraKine
News

RBCC Forms Joint Venture with Cutting-Edge Drug Delivery Company TheraKine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RBCC Forms Joint Venture with Cutting-Edge Drug Delivery Company TheraKine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RBCC signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. The company has developed and patented these novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

Additionally, this new sustained-release technology can also extend the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.

“TheraKine’s sustained-release delivery system could allow patients who now need daily injections to instead have one injection every four to six months,” said RBCC CEO Patrick Brown. “We expect the demand for this product to be very high once it’s made available, and RBCC plans to take a real stake in its success.”

Stan Yakatan, TheraKine's CEO, said, "TheraKine is excited about the opportunity to partner with Rainbow to repurpose drugs with our sustained release technologies."

RBCC is dedicated to delivering new medical research and technologies to a hungry global marketplace.

Advertisement